The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study

The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study

BackgroundRandomized clinical trials of spironolactone showed significant mortality reduction in patients with heart failure with reduced ejection fraction. However, its role in acute heart failure syndrome (AHFS) is largely unknown.AimTo investigate the prescription characteristics, efficacy and sa...

Full description

Bibliographic Details
Main Authors:	Soo Jin Na, Jong-Chan Youn, Hye Sun Lee, Soyoung Jeon, Hae-Young Lee, Hyun-Jai Cho, Jin-Oh Choi, Eun-Seok Jeon, Sang Eun Lee, Min-Seok Kim, Jae-Joong Kim, Kyung-Kuk Hwang, Myeong-Chan Cho, Shung Chull Chae, Seok-Min Kang, Dong-Ju Choi, Byung-Su Yoo, Kye Hun Kim, Byung-Hee Oh, Sang Hong Baek
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-02-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	acute heart failure syndrome spironolactone mineralocorticoid receptor antagonists drug therapy outcome
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2022.791446/full

Similar Items

Corrigendum: The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study
by: Soo Jin Na, et al.
Published: (2022-04-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes
by: Mengyue Lin, et al.
Published: (2021-05-01)

Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients
by: Sun Z, et al.
Published: (2023-01-01)

Efficacy and Safety of Spironolactone in the Treatment of Resistant Hypertension：a Meta-analysis
by: ZHANG Ping, ZOU Jing, GAO Cunzhou, WU Aiping, LI Rongshan
Published: (2022-03-01)

Spironolactone as an Adjunctive Treatment in Neovascular Age-Related Macular Degeneration
by: Kapil G. Kapoor, et al.
Published: (2017-05-01)

Spironolactone-Induced Agranulocytosis: A Case Report
by: Shu-Hwa Hsiao, et al.
Published: (2003-11-01)

Novel Insights into the Role of the Mineralocorticoid Receptor in Human Glioblastoma
by: Paula Aldaz, et al.
Published: (2021-10-01)

Prognostic Impact and Predictors of New-Onset Atrial Fibrillation in Heart Failure
by: Hyo-In Choi, et al.
Published: (2022-04-01)

In-hospital glycemic variability and all-cause mortality among patients hospitalized for acute heart failure
by: Kyeong-Hyeon Chun, et al.
Published: (2022-12-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
by: V. N. Soboleva, et al.
Published: (2015-01-01)

Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research
by: Argen Mamazhakypov, et al.
Published: (2023-01-01)

Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
by: Mohamad El Wardani, et al.
Published: (2023-03-01)

The paradox of spironolactone: A heart failure treatment with potentially harmful effects
by: Muhammad Roshan, et al.
Published: (2024-01-01)

The paradox of spironolactone: A heart failure treatment with potentially harmful effects
by: Muhammad Roshan, et al.
Published: (2024-01-01)

Possible role of Spironolactone in a sample of Iraqi patients with acute central serous chorioretinopathy
by: Marwa Majeed Hameed, et al.
Published: (2022-05-01)

Association of spironolactone treatment and arterial stiffness and cardiovascular disease in hypertensive patients
by: Fanfang Zeng, et al.
Published: (2019-06-01)

Influence of Different Treatment Strategies on New‐Onset Atrial Fibrillation Among Patients With Primary Aldosteronism: A Nationwide Longitudinal Cohort‐Based Study
by: Chien‐Ting Pan, et al.
Published: (2020-03-01)

Enantioselective Organocatalyzed Michael Addition of Isobutyraldehyde to Maleimides in Aqueous Media
by: Jae Ho Shim, et al.
Published: (2022-04-01)

Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials
by: Liping Liu, et al.
Published: (2017-04-01)

Comparative evaluation of captopril, spironolactone, and carvedilol effect on endothelial function in breast cancer women undergoing chemotherapy
by: Seyed Mohammad Hashemi Jazi, et al.
Published: (2023-01-01)

Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence
by: Laura E. J. Peeters, et al.
Published: (2022-01-01)

β‐Blockers and 1‐Year Postdischarge Mortality for Heart Failure and Reduced Ejection Fraction and Slow Discharge Heart Rate
by: Jin Joo Park, et al.
Published: (2019-02-01)

The Effect of Spironolactone on Control of Pulmonary Hypertension in Patients with Obstructive Pulmonary Disease
by: Mohammad Emami, et al.
Published: (2019-01-01)

Diuretic Effect of Prosopis farcta in Comparison with Spironolactone and Hydrochlorothiazide in Hypertensive Rats
by: Zana M.Raoof, et al.
Published: (2020-06-01)

Modified reverse shock index predicts early outcomes of heart failure with reduced ejection fraction
by: Gyu Chul Oh, et al.
Published: (2022-10-01)

Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis
by: Jean Kim, et al.
Published: (2022-03-01)

Association between Use of Spironolactone and Risk of Stroke in Hypertensive Patients: A Cohort Study
by: Xintian Cai, et al.
Published: (2022-12-01)

Spironolactone as a Potential New Treatment to Prevent Arrhythmias in Arrhythmogenic Cardiomyopathy Cell Model
by: Jean-Baptiste Reisqs, et al.
Published: (2023-02-01)

Investigating the Effect of Coated Lipid Nano Particles of Spironolactone with Chitosan on Their Properties
by: Reza Enayatifard, et al.
Published: (2018-07-01)

Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China—The China PEACE Retrospective Heart Failure Study
by: Yuan Yu, et al.
Published: (2022-10-01)

Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?
by: Giuseppe Remuzzi, et al.
Published: (2010-01-01)

ALDOSTERONE ANTAGONISTS. MODERN VIEWS ON THE MECHANISM OF ACTION AND EFFECTS OF SPIRONOLACTONE
by: V. I. Podzolkov, et al.
Published: (2017-05-01)

Effectiveness of spironolactone on schizophrenia symptoms: A double-blind randomized clinical trial
by: Nazanin Hoghoughi, et al.
Published: (2023-08-01)

Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
by: Hui‐min Zhou, et al.
Published: (2023-02-01)

Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model
by: Stephanie E. Areloegbe, et al.
Published: (2022-09-01)

Impact of Cardiac Troponin Elevation on Mortality of Patients with Acute Heart Failure: Insights from the Korea Acute Heart Failure (KorAHF) Registry
by: Nuri Lee, et al.
Published: (2022-05-01)

C-reactive protein and statins in heart failure with reduced and preserved ejection fraction
by: Jin Joo Park, et al.
Published: (2022-12-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)